

# Shlomo Melmed

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3523164/shlomo-melmed-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234 papers	19,162 citations	73 h-index	135 g-index
251 ext. papers	22,271 ext. citations	9 avg, IF	7.32 L-index

#	Paper	IF	Citations
234	Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.. <i>Pituitary</i> , <b>2022</b> , 1	4.3	2
233	Clinical Biology of the Pituitary Adenoma.. <i>Endocrine Reviews</i> , <b>2022</b> ,	27.2	3
232	GH and Senescence: A New Understanding of Adult GH Action.. <i>Journal of the Endocrine Society</i> , <b>2022</b> , 6, bvab177	0.4	0
231	Safety of growth hormone replacement in survivors of cancer and intra-cranial and pituitary tumours - A consensus statement.. <i>European Journal of Endocrinology</i> , <b>2022</b> ,	6.5	4
230	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,	18.1	6
229	Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage.. <i>Cell Reports</i> , <b>2021</b> , 37, 110068	10.6	0
228	Prospective Evaluation of Incidental Pituitary Imaging Findings in the Sella Turcica. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvaa186	0.4	9
227	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 847-875	18.1	48
226	Insulin-like Growth Factor 1 and Prolactin Levels in Chimpanzees (Pan troglodytes) Across the Lifespan. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvab063	0.4	1
225	Pituitary Somatotroph Adenoma Cell-Derived Exosomes: Characterization of Novel Non-Hormonal Functions. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A652-A653	0.4	78
224	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A518-A519	0.4	1
223	The Pharmacological Burden of Comorbidities in Acromegaly. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A649-A650	0.4	2
222	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands Results From the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A522-A523	0.4	78
221	GH Is a Component of SASP in Aging Tissue. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A539-A540	0.4	78
220	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A527-A528	0.4	78
219	Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e3346-e3363	5.6	5
218	International Multicenter Validation Study of the SAGIT <sup>®</sup> Instrument in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 3555-3568	5.6	1

217	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e917-e925	5.6	16
216	A Pituitary Society update to acromegaly management guidelines. <i>Pituitary</i> , <b>2021</b> , 24, 1-13	4.3	50
215	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvaa205	0.4	14
214	Pituitary somatotroph adenoma-derived exosomes: characterization of nonhormonal actions. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	1
213	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178 Suppl 1, S27-S156	8.6	46
212	Pituitary stem cells. <i>Vitamins and Hormones</i> , <b>2021</b> , 116, 1-19	2.5	1
211	Orchestrates Gene Regulatory Variation in Mouse Ventral Midbrain During Aging. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 566734	4.5	2
210	MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
209	Pituitary-Tumor Endocrinopathies. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 937-950	59.2	155
208	OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	1
207	DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5738-5755	15.9	17
206	MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	1
205	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
204	OR16-06 Age-Associated Local GH Promotes Colon Neoplasia. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
203	MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
202	MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
201	MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
200	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. <i>Pituitary</i> , <b>2020</b> , 23, 476-477	4.3	12

199	Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	10
198	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2020</b> , 21, 667-678	10.5	67
197	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	29
196	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	88
195	Peptide Hormone Regulation of DNA Damage Responses. <i>Endocrine Reviews</i> , <b>2020</b> , 41,	27.2	5
194	A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement. <i>Pituitary</i> , <b>2019</b> , 22, 569-573	4.3	41
193	Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2551-2562	59.2	46
192	Growth Hormone Induces Colon DNA Damage Independent of IGF-1. <i>Endocrinology</i> , <b>2019</b> , 160, 1439-1447.	7.8	13
191	Plurihormonal Adenomas. <i>Contemporary Endocrinology</i> , <b>2019</b> , 205-217	0.3	1
190	Acromegaly. <i>Nature Reviews Disease Primers</i> , <b>2019</b> , 5, 20	51.1	128
189	Excess growth hormone suppresses DNA damage repair in epithelial cells. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	21
188	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT validation study. <i>Pituitary</i> , <b>2019</b> , 22, 476-487	4.3	13
187	MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	3
186	SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	5
185	Growth hormone in the tumor microenvironment. <i>Archives of Endocrinology and Metabolism</i> , <b>2019</b> , 63, 568-575	2.2	10
184	Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice. <i>Endocrinology</i> , <b>2019</b> , 160, 276-291	4.8	3
183	A Consensus Statement on acromegaly therapeutic outcomes. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 552-561	15.2	216
182	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. <i>Pharmacological Reviews</i> , <b>2018</b> , 70, 763-835	22.5	101

181	THYMIC CARCINOID WITH ADRENOCORTICOTROPIC HORMONE-PRODUCING ECTOPIC CUSHING SYNDROME AND EMPTY SELLA. <i>AACE Clinical Case Reports</i> , <b>2018</b> , 4, e375-e378	0.7	2
180	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. <i>Endocrinology</i> , <b>2017</b> , 158, 2255-2268	4.8	14
179	Melvin M. Grumbach 1925-2016. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 4845-4847	11.5	
178	Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. <i>Pituitary</i> , <b>2017</b> , 20, 93-99	4.3	17
177	Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. <i>Neurosurgery</i> , <b>2017</b> , 81, 357-366	3.2	39
176	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. <i>Pituitary</i> , <b>2017</b> , 20, 489-498	4.3	157
175	Growth Hormone <b>2017</b> , 85-127		5
174	EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis. <i>Journal of the Endocrine Society</i> , <b>2017</b> , 1, 127-143	14.3	27
173	Altered Pituitary Gland Structure and Function in Posttraumatic Stress Disorder. <i>Journal of the Endocrine Society</i> , <b>2017</b> , 1, 577-587	0.4	12
172	Clinically Nonfunctioning Sellar Masses <b>2016</b> , 256-265.e3		
171	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 3888-3921	5.6	404
170	E2F1-mediated human POMC expression in ectopic Cushing's syndrome. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 857-870	5.7	16
169	SAGIT <sup>®</sup> : clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. <i>Pituitary</i> , <b>2016</b> , 19, 39-49	4.3	37
168	Pituitary Medicine From Discovery to Patient-Focused Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 769-77	5.6	30
167	New therapeutic agents for acromegaly. <i>Nature Reviews Endocrinology</i> , <b>2016</b> , 12, 90-8	15.2	46
166	Pituitary Masses and Tumors <b>2016</b> , 232-299		13
165	Growth hormone is permissive for neoplastic colon growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3250-9	11.5	52
164	Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 2557-64	5.6	44

163	Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1699-708	5.6	114
162	Pituitary tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2015</b> , 44, 1-9	5.5	53
161	Endocrinology research-reflecting on the past decade and looking to the next. <i>Nature Reviews Endocrinology</i> , <b>2015</b> , 11, 672-80	15.2	2
160	ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. <i>Endocrinology</i> , <b>2015</b> , 156, 71-9	4.8	29
159	STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1692-702	15.9	39
158	A structural and functional acromegaly classification. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 122-31	5.6	63
157	Fertility and fragrance: another cause of Kallmann syndrome. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 2275-8	15.9	2
156	Acromegaly: assessing the disorder and navigating therapeutic options for treatment. <i>Endocrine Practice</i> , <b>2014</b> , 20 Suppl 1, 7-17; quiz 18-20	3.2	17
155	Expert consensus document: A consensus on the medical treatment of acromegaly. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 243-8	15.2	255
154	Acromegaly: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3933-51	5.6	923
153	Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 1825-33	5.6	106
152	Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 9295-300	11.5	20
151	Genetic Factors in Cushing Disease Pathogenesis <b>2014</b> , 365-371		
150	Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. <i>Molecular Endocrinology</i> , <b>2014</b> , 28, 554-64		12
149	Sca1+ murine pituitary adenoma cells show tumor-growth advantage. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, 203-16	5.7	18
148	Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 754-762	2.4	9
147	Idiopathic adult growth hormone deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 2187-97	5.6	39
146	Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 980-8	5.6	66

145	Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E3331-9	11.5	45
144	Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. <i>Molecular Endocrinology</i> , <b>2012</b> , 26, 2092-103		23
143	Subclinical hyperfunctioning pituitary adenomas: the silent tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 26, 447-60	6.5	54
142	Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. <i>Endocrinology</i> , <b>2012</b> , 153, 5011-22	4.8	6
141	Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 362, 104-9	4.4	23
140	Genomic characterization of human and rat prolactinomas. <i>Endocrinology</i> , <b>2012</b> , 153, 3679-91	4.8	24
139	Pituitary Adenomas <b>2012</b> , 739-760		1
138	Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2990-3011	5.6	830
137	Meta-analysis on the effects of octreotide on tumor mass in acromegaly. <i>PLoS ONE</i> , <b>2012</b> , 7, e36411	3.7	128
136	A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3295-306	15.9	47
135	Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 273-88	5.6	967
134	Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 1633-41	5.6	150
133	Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. <i>PLoS ONE</i> , <b>2011</b> , 6, e17924	3.7	42
132	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4712-21	15.9	177
131	Pathogenesis of pituitary tumors. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 7, 257-66	15.2	336
130	CEBPD suppresses prolactin expression and prolactinoma cell proliferation. <i>Molecular Endocrinology</i> , <b>2011</b> , 25, 1880-91		16
129	Growth Hormone <b>2011</b> , 83-117		3
128	Expression and function of ErbB receptors and ligands in the pituitary. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, R197-211	5.7	51



127	Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 8414-15	11.5	99
126	Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. <i>PLoS Genetics</i> , <b>2011</b> , 7, e1001271	6	36
125	HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. <i>Molecular Endocrinology</i> , <b>2011</b> , 25, 92-103		52
124	PTTG1 attenuates drug-induced cellular senescence. <i>PLoS ONE</i> , <b>2011</b> , 6, e23754	3.7	18
123	Pituitary Physiology and Diagnostic Evaluation <b>2011</b> , 175-228		20
122	Pituitary Masses and Tumors <b>2011</b> , 229-290		3
121	Molecular Biology of Cushing's Disease. <i>Growth Hormone</i> , <b>2011</b> , 19-32		
120	Pathogenesis of pituitary tumors. <i>Progress in Brain Research</i> , <b>2010</b> , 182, 207-27	2.9	22
119	Constitutive activity of somatostatin receptor subtypes. <i>Methods in Enzymology</i> , <b>2010</b> , 484, 149-64	1.7	9
118	Pituitary senescence: the evolving role of Pttg. <i>Molecular and Cellular Endocrinology</i> , <b>2010</b> , 326, 55-9	4.4	34
117	Pituitary somatostatin receptor signaling. <i>Trends in Endocrinology and Metabolism</i> , <b>2010</b> , 21, 123-33	8.8	149
116	Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. <i>Hormones and Cancer</i> , <b>2010</b> , 1, 80-92	5	62
115	Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. <i>Pituitary</i> , <b>2010</b> , 13, 18-28	4.3	102
114	The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. <i>Pituitary</i> , <b>2010</b> , 13, 266-86	4.3	7
113	Pathogenesis of Corticotrophic Tumors <b>2010</b> , 31-40		
112	Clinically Nonfunctioning Sellar Masses <b>2010</b> , 312-323		
111	Acromegaly pathogenesis and treatment. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 3189-202	15.9	424
110	E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. <i>Molecular Endocrinology</i> , <b>2009</b> , 23, 2000-12		32



109	Constitutive somatostatin receptor activity determines tonic pituitary cell response. <i>Molecular Endocrinology</i> , <b>2009</b> , 23, 337-48		27
108	Heregulin regulates prolactinoma gene expression. <i>Cancer Research</i> , <b>2009</b> , 69, 4209-16	10.1	31
107	Fibroblast growth factor-2 autocrine feedback regulation in pituitary folliculostellate TtT/GF cells. <i>Endocrinology</i> , <b>2009</b> , 150, 3252-8	4.8	12
106	Pituitary adenoma growth: A model for cellular senescence and cytokine action. <i>Cell Cycle</i> , <b>2009</b> , 8, 677-682	4.7	20
105	Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 392-9	5.6	45
104	The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 523-7	5.6	120
103	Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2008</b> , 37, 101-22, viii	5.5	163
102	A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2957-68	5.6	152
101	Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. <i>Cancer Research</i> , <b>2008</b> , 68, 6377-86	10.1	59
100	In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. <i>Developmental Biology</i> , <b>2008</b> , 319, 192-200	3.1	16
99	Somatostatin agonists for treatment of acromegaly. <i>Molecular and Cellular Endocrinology</i> , <b>2008</b> , 286, 192-8	4.4	76
98	p21(Cip1) restrains pituitary tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 17498-503	11.5	120
97	Pituitary hormone receptors and tumorigenesis. <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 722-722	31.3	1
96	Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. <i>American Journal of Physiology - Cell Physiology</i> , <b>2007</b> , 293, C1082-92	5.4	11
95	Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 1617-9	5.6	5
94	Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. <i>Molecular Endocrinology</i> , <b>2007</b> , 21, 2565-78		36
93	Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. <i>Cancer Research</i> , <b>2007</b> , 67, 10564-72	10.1	91
92	Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. <i>Endocrine Reviews</i> , <b>2007</b> , 28, 165-86	27.2	202

91	Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2007</b> , 10, 885-95		13
90	Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. <i>Endocrinology</i> , <b>2006</b> , 147, 4781-91	4.8	59
89	Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2006</b> , 2, 408-12; quiz following 412		10
88	Skin manifestations in acromegaly. <i>Clinics in Dermatology</i> , <b>2006</b> , 24, 256-9	3	50
87	The Pituitary <b>2006</b> ,		2
86	Medical progress: Acromegaly. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2558-73	59.2	850
85	Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism. <i>Endocrine</i> , <b>2006</b> , 29, 119-20		1
84	2004 World Health Organization classification of pituitary tumors: what is new?. <i>Acta Neuropathologica</i> , <b>2006</b> , 111, 78-9	14.3	2
83	A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. <i>Journal of Surgical Research</i> , <b>2005</b> , 129, 142-6	2.5	18
82	Treatment of acromegaly: future. <i>Endocrine</i> , <b>2005</b> , 28, 123-8		26
81	Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. <i>Molecular Endocrinology</i> , <b>2005</b> , 19, 1383-91		95
80	Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 24011-21	5.4	42
79	A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 4405-10	5.6	168
78	Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. <i>Molecular Endocrinology</i> , <b>2005</b> , 19, 2371-9		115
77	The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3027-32	5.6	71
76	Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3397-401	5.6	104
75	Molecular targets in pituitary tumours. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 285-95	31.3	99
74	Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 349-56	15.9	111

73	Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. <i>Molecular Endocrinology</i> , <b>2003</b> , 17, 600-9		30
72	Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5414-21	5.6	73
71	The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3724-30	5.6	33
70	Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4239-45	5.6	72
69	Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. <i>Endocrinology</i> , <b>2003</b> , 144, 4991-8	4.8	107
68	Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 963-8	5.6	51
67	Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4759-67	5.6	71
66	Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 3428-32	11.5	75
65	PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1381-8	15.9	55
64	PPAR- $\gamma$ receptor ligands: novel therapy for pituitary adenomas. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1381-1388	15.9	116
63	Mechanisms for pituitary tumorigenesis: the plastic pituitary. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 112, 1603-18	15.9	291
62	Acromegaly Consensus: The Next Steps. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1913-1914	5.6	10
61	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. <i>Nature Medicine</i> , <b>2002</b> , 8, 1281-7	50.5	202
60	Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells. <i>Endocrine Pathology</i> , <b>2002</b> , 13, 197-206	4.2	16
59	Molecular pathogenesis of pituitary disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2002</b> , 9, 61-78		5
58	Functional role of estrogen in pituitary tumor pathogenesis. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 109, 277-283	15.9	117
57	Functional role of estrogen in pituitary tumor pathogenesis. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 109, 277-83	15.9	71
56	Oncogene activation in pituitary tumors. <i>Brain Pathology</i> , <b>2001</b> , 11, 328-41	6	54

55	Growth Hormone Excess and Cancer. <i>Rejuvenation Research</i> , <b>2001</b> , 4, 373-381		2
54	Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. <i>Molecular Endocrinology</i> , <b>2001</b> , 15, 1870-9		161
53	Human pituitary tumor-transforming gene induces angiogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 867-74	5.6	108
52	Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. <i>Lancet, The</i> , <b>2001</b> , 358, 1754-9	4.0	499
51	The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 108, 1735-1740	15.9	58
50	Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study. <i>Pituitary</i> , <b>2000</b> , 2, 245-51	4.3	11
49	Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3409-16	5.6	17
48	Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter. <i>Endocrinology</i> , <b>2000</b> , 141, 763-71	4.8	20
47	Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 2958-61	5.6	73
46	Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 7459-61	5.4	41
45	Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 36502-5	5.4	84
44	Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. <i>Molecular Endocrinology</i> , <b>2000</b> , 14, 1137-46		88
43	Criteria for cure of acromegaly: a consensus statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 526-9	5.6	727
42	Expression of pituitary-tumour transforming gene in colorectal tumours. <i>Lancet, The</i> , <b>2000</b> , 355, 716-9	4.0	206
41	Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 106, 1417-25	15.9	80
40	gp130-Related Cytokines <b>2000</b> , 115-132		
39	Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 104, 1277-85	15.9	82
38	An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1149-52	5.6	41

37	Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. <i>Endocrinology</i> , <b>1999</b> , 140, 1559-66	4.8	64
36	Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 249-56	5.6	68
35	Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). <i>Molecular Endocrinology</i> , <b>1999</b> , 13, 156-66		241
34	Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 761-7	5.6	314
33	Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. <i>Nature Medicine</i> , <b>1999</b> , 5, 1317-21	50.5	279
32	Molecular pathogenesis of acromegaly. <i>Pituitary</i> , <b>1999</b> , 2, 43-50	4.3	7
31	Expression of leukemia inhibitory factor in craniopharyngioma. <i>Endocrine Pathology</i> , <b>1999</b> , 10, 103-8	4.2	4
30	Pathogenesis of pituitary tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1999</b> , 28, 1-12, v	5.5	21
29	Stimulatory effect of leukemia inhibitory factor on ACTH secretion of dispersed rat pituitary cells. <i>Endocrine Research</i> , <b>1999</b> , 25, 11-9	1.9	15
28	Leukemia inhibitory factor regulates proopiomelanocortin transcription. <i>Annals of the New York Academy of Sciences</i> , <b>1998</b> , 840, 162-73	6.5	25
27	Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. <i>Clinical Endocrinology</i> , <b>1998</b> , 48, 23-9	3.4	37
26	Pregnancy in acromegaly: successful therapeutic outcome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 727-31	5.6	81
25	Octreotide as primary therapy for acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 3034-40	5.6	181
24	Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 1388-91	5.6	115
23	Pituitary Function and Neoplasia <b>1998</b> , 443-449		3
22	Pituitary cytokine and growth factor expression and action. <i>Endocrine Reviews</i> , <b>1997</b> , 18, 206-28	27.2	170
21	Isolation and characterization of a pituitary tumor-transforming gene (PTTG). <i>Molecular Endocrinology</i> , <b>1997</b> , 11, 433-41		458
20	A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 10551-7	5.47	55

19	Genetic basis of endocrine disease: pituitary tumor pathogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 1675-81	5.6	107
18	Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF. <i>Endocrine</i> , <b>1997</b> , 7, 325-30		6
17	Oncogenes and Tumor Suppressor Genes in Pituitary Tumorigenesis. <i>Frontiers of Hormone Research</i> , <b>1996</b> , 20, 122-136	3.5	4
16	Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas. <i>Clinical Endocrinology</i> , <b>1996</b> , 44, 341-7	3.4	25
15	The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. <i>Clinical Endocrinology</i> , <b>1995</b> , 42, 169-72	3.4	10
14	Pituitary Neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1994</b> , 23, 81-92	5.5	17
13	Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. <i>Cancer</i> , <b>1993</b> , 71, 66-70	6.4	27
12	Transforming DNA sequences present in human prolactin-secreting pituitary tumors. <i>Molecular Endocrinology</i> , <b>1991</b> , 5, 1687-95		63
11	In vivo regulation of hepatic insulin-like growth factor-1 messenger ribonucleic acids with thyroid hormone. <i>Endocrinologia Japonica</i> , <b>1990</b> , 37, 205-11		24
10	Clonal origin of pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1990</b> , 71, 1427-33	5.6	458
9	Acromegaly. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 966-77	59.2	481
8	Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1988</b> , 67, 395-9	5.6	40
7	Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. <i>New England Journal of Medicine</i> , <b>1985</b> , 312, 9-17	59.2	121
6	Localization of somatostatin receptors in secretion vesicles in anterior pituitary cells and pancreatic islets. <i>Journal of Receptors and Signal Transduction</i> , <b>1985</b> , 5, 83-103		19
5	Pathophysiology of acromegaly. <i>Endocrine Reviews</i> , <b>1983</b> , 4, 271-90	27.2	130
4	Establishment of functional human pituitary tumor cell cultures. <i>In Vitro</i> , <b>1982</b> , 18, 35-42		6
3	Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. <i>Endocrine Abstracts</i> ,		4
2	Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly. <i>Endocrine Abstracts</i> ,		2

1	A Consensus Statement on acromegaly therapeutic outcomes	1
---	--	---